164 related articles for article (PubMed ID: 11318115)
41. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman J; Onaitis MW; Tyler DS; Olson JA
Cancer; 2004 Nov; 101(9):1987-93. PubMed ID: 15455358
[TBL] [Abstract][Full Text] [Related]
42. 123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, beta-, or gamma-radiation-resistant cell lines.
Reske SN; Deisenhofer S; Glatting G; Zlatopolskiy BD; Morgenroth A; Vogg AT; Buck AK; Friesen C
J Nucl Med; 2007 Jun; 48(6):1000-7. PubMed ID: 17504875
[TBL] [Abstract][Full Text] [Related]
43. Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination.
McCluskey AG; Boyd M; Pimlott SL; Babich JW; Gaze MN; Mairs RJ
Br J Radiol; 2008 Oct; 81 Spec No 1():S28-35. PubMed ID: 18819996
[TBL] [Abstract][Full Text] [Related]
44. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine.
Garaventa A; Gambini C; Villavecchia G; Di Cataldo A; Bertolazzi L; Pizzitola MR; De Bernardi B; Haupt R
Cancer; 2003 Mar; 97(5):1332-8. PubMed ID: 12599242
[TBL] [Abstract][Full Text] [Related]
45. Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy.
Carlsson J; Eriksson V; Stenerlöw B; Lundqvist H
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1185-95. PubMed ID: 16718515
[TBL] [Abstract][Full Text] [Related]
46. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA
Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341
[TBL] [Abstract][Full Text] [Related]
47. Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.
Strickland DK; Vaidyanathan G; Friedman HS; Zalutsky MR
J Neurooncol; 1995; 25(1):9-17. PubMed ID: 8523094
[TBL] [Abstract][Full Text] [Related]
48. Action and efficacy of p-[131I]iodo-L-phenylalanine on primary human glioma cell cultures and rats with C6-gliomas.
Romeike BF; Hellwig D; Heimann A; Kempski O; Feiden W; Kirsch CM; Samnick S
Anticancer Res; 2004; 24(6):3971-6. PubMed ID: 15736441
[TBL] [Abstract][Full Text] [Related]
49. Combined radiation and cytochrome CYP4B1/4-ipomeanol gene therapy using the EGR1 promoter.
Hsu H; Rainov NG; Quinones A; Eling DJ; Sakamoto KM; Spear MA
Anticancer Res; 2003; 23(3B):2723-8. PubMed ID: 12894565
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of systemic radionuclide therapy with p-131I-iodo-L-phenylalanine combined with external beam photon irradiation in treating malignant gliomas.
Samnick S; Romeike BF; Lehmann T; Israel I; Rübe C; Mautes A; Reiners C; Kirsch CM
J Nucl Med; 2009 Dec; 50(12):2025-32. PubMed ID: 19910430
[TBL] [Abstract][Full Text] [Related]
51. The effects of irradiation on cell migration from glioblastoma multiforme biopsy spheroids.
Kleynen CE; Stoter TR; Tadema TM; Stalpers LJ; Dirven CM; Leenstra S; Van Der Valk P; Slotman BJ; Sminia P
Anticancer Res; 2003; 23(6C):4907-12. PubMed ID: 14981944
[TBL] [Abstract][Full Text] [Related]
52. The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells.
Rae C; Tesson M; Babich JW; Boyd M; Sorensen A; Mairs RJ
J Nucl Med; 2013 Jun; 54(6):953-60. PubMed ID: 23616582
[TBL] [Abstract][Full Text] [Related]
53. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma.
Howard JP; Maris JM; Kersun LS; Huberty JP; Cheng SC; Hawkins RA; Matthay KK
Pediatr Blood Cancer; 2005 Mar; 44(3):232-9. PubMed ID: 15490487
[TBL] [Abstract][Full Text] [Related]
54. Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species.
Rae C; Tesson M; Babich JW; Boyd M; Mairs RJ
EJNMMI Res; 2013 Nov; 3(1):73. PubMed ID: 24219987
[TBL] [Abstract][Full Text] [Related]
55. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
Matthay KK; Panina C; Huberty J; Price D; Glidden DV; Tang HR; Hawkins RA; Veatch J; Hasegawa B
J Nucl Med; 2001 Nov; 42(11):1713-21. PubMed ID: 11696644
[TBL] [Abstract][Full Text] [Related]
56. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
Mitrofanova E; Unfer R; Vahanian N; Link C
Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
[TBL] [Abstract][Full Text] [Related]
57. Meta-iodobenzylguanidine derivatives containing a second guanidine moiety.
Vaidyanathan G; Shankar S; Affleck DJ; Alston K; Norman J; Welsh P; LeGrand H; Zalutsky MR
Bioorg Med Chem; 2004 Apr; 12(7):1649-56. PubMed ID: 15028258
[TBL] [Abstract][Full Text] [Related]
58. Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma.
Gaze MN; Gains JE; Walker C; Bomanji JB
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):66-78. PubMed ID: 23474636
[TBL] [Abstract][Full Text] [Related]
59. No-carrier-added 123I-MIBG: an initial clinical study in patients with phaeochromocytoma.
Owens J; Bolster AA; Prosser JE; Cunningham S; Mairs RJ; Neilly JB; Reed NS; Hilditch TE
Nucl Med Commun; 2000 May; 21(5):437-40. PubMed ID: 10874700
[TBL] [Abstract][Full Text] [Related]
60. Differential cytotoxicity of [123I]IUdR, [125I]IUdR and [131I]IUdR to human glioma cells in monolayer or spheroid culture: effect of proliferative heterogeneity and radiation cross-fire.
Neshasteh-Riz A; Mairs RJ; Angerson WJ; Stanton PD; Reeves JR; Rampling R; Owens J; Wheldon TE
Br J Cancer; 1998; 77(3):385-90. PubMed ID: 9472632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
